Logged on as:   Login
You are here: Home

Welcome to the GetReal Website!

Launched in October 2013, GetReal is a three-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and ZIN), patient organisations and SMEs.

GetReal aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process. The consortium is doing this by:

  • Bringing together healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Assessing existing processes, methodologies, and key research issues;
  • Proposing innovative trial designs and assessing the value of information;
  • Proposing and testing innovative analytical and predictive modelling approaches;
  • Assessing operational challenges and proposing and testing the impact of solutions;
  • Creating new decision making support, and building tools to allow for the evaluation of development programmes and use in the assessment of the value of introducing new treatments;
  • Sharing and discussing deliverables with healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Developing training for researchers, healthcare decision makers and societal stakeholders in the public and private sector in order to increase knowledge about various aspects of effectiveness.

Latest News

GetReal vacancy at NICE: Scientific Project Manager

Posted on August 25, 2015 12:11
The National Institute for Health and Care Excelle...  

Response from WP3 to article about PRECIS-2 tool published online by BMJ

Posted on August 04, 2015 14:33
The rapid response from WP3 entitled “Pragma...  

New WP1 co-lead

Posted on July 08, 2015 10:01
WP1 will have a new project co-lead from July 2015...  

Funding


           

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115546], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.